FILTER BY:
Details
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Address: 10 Center Dr, Bethesda, MD 20892, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: False
- Peritoneal: False
- Pericardial: False
- Tunica Vaginalis: False
Type: Epitheliod, Biphasic, Sarcomatoid
Condition: Mesothelioma, Malignant Mesothelioma, Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Description: This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated....
Research Center: National Institutes of Health Clinical Center
Treatment Interventions: DRUG: Decitabine/cedazuridine
Potential Impact: Low
Clinical Trial Number: NCT05960773
Phase: Phase 2
Status: Recruiting
